Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.
Juluca is a single-tablet regimen for HIV.
A recent study tested the long-acting injectable antiretrovirals cabotegravir and Edurant (rilpivirine) given every four or eight weeks.
Cabotegravir and rilpivirine combo shows promise as well-tolerated and effective antiretroviral regimen in a trial.
Two large trials switched participants from three- or four-drug combos to a regimen of Tivicay (dolutegravir) and Edurant (rilpivirine).
Long-term Viread (tenofovir disoproxil fumarate, or TDF) use is linked with a raised risk of end-stage liver cancer in HIV-positive people.
ViiV Healthcare and Janssen have formalized their collaboration agreement to develop a long-acting, two-drug injectable HIV treatment.
Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.
What does the future hold for new pre-exposure prophylaxis (PrEP) against HIV, including long-acting injectables and less toxic drugs?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.